RB1 and neoplasm: These effects force permanent cell cycle exit and disrupt immunosuppressive tumor microenvironment, translating synergistic efficacy against RB-proficient and RB-deficient TNBC, paving the way for new clinical trials to evaluate their clinical impact on patients with TNBC.